The DOI matches its Crossref record.
Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection
Open accessAbstract
Objective: The reverse transcriptase inhibitor efavirenz is currently used at a fixed dose of 600 mg/d. However, dosage individualization based on plasma concentration monitoring might be indicated. This study aimed to assess the efavirenz pharmacokinetic profile and interpatient versus intrapatient variability in patients who are positive for human immunodeficiency virus, to explore the relationship between drug exposure, efficacy, and central nervous system toxicity and to build up a Bayesian approach for dosage adaptation. Methods: The population pharmacokinetic analysis was performed by use of NONMEM based on plasma samples from a cohort of unselected patients receiving efavirenz. With the use of a 1‐compartment model with first‐order absorption, the influence of demographic and clinical characteristics on oral clearance and oral volume of distribution was examined. The average drug exposure during 1 dosing interval was estimated for each patient and correlated with markers of efficacy and toxicity. The population kinetic parameters and the variabilities were integrated into a Bayesian equation for dosage adaptation based on a single plasma sample. Results: Data from 235 patients with a total of 719 efavirenz concentrations were collected. Oral clearance was 9.4 L/h, oral volume of distribution was 252 L, and the absorption rate constant was 0.3 h−1. Neither the demographic covariates evaluated nor the comedications showed a clinically significant influence on efavirenz pharmacokinetics. A large interpatient variability was found to affect efavirenz relative bioavailability (coefficient of variation, 54.6%), whereas the intrapatient variability was small (coefficient of variation, 26%). An inverse correlation between average drug exposure and viral load and a trend with central nervous system toxicity were detected. This enabled the derivation of a dosing adaptation strategy suitable to bring the average concentration into a therapeutic target from 1000 to 4000 μg/L to optimize viral load suppression and to minimize central nervous system toxicity. Conclusions: The high interpatient and low intrapatient variability values, as well as the potential relationship with markers of efficacy and toxicity, support the therapeutic drug monitoring of efavirenz. However, further evaluation is needed before individualization of an efavirenz dosage regimen based on routine drug level monitoring should be recommended for optimal patient management. Clinical Pharmacology & Therapeutics (2003) 73, 20–30; doi: 10.1067/mcp.2003.22
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Klein, K., Lang, T., Saussele, T., Barbosa-Sicard, E., Schunck, W.-H., Eichelbaum, M., Schwab, M., & Zanger, U. M. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200512000-00004 · Cited by 269
Scott, S. A., Sangkuhl, K., Shuldiner, A. R., Hulot, J.-S., Thorn, C. F., Altman, R. B., & Klein, T. E. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834d4962 · Cited by 261
Polymorphic CYP2B6: Molecular Mechanisms and Emerging Clinical Significance
Zanger, U. M., Klein, K., Saussele, T., Blievernicht, J., H Hofmann, M., & Schwab, M. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.7.743 · Cited by 258
Rotger, M., Tegude, H., Colombo, S., Cavassini, M., Furrer, H., Décosterd, L., Blievernicht, J., Saussele, T., Günthard, H. F., Schwab, M., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100072 · Cited by 257
Self-citationOral pharmacokinetics of the anti-HIV efavirenz encapsulated within polymeric micelles
Chiappetta, D. A., Hocht, C., Taira, C., & Sosnik, A. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.11.082 · Cited by 124
Metadata
- Authors
- Csajka, C., Marzolini, C., Fattinger, K., Décosterd, L. A., Fellay, J., Telenti, A., Biollaz, J., & Buclin, T.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2003-01
- Volume
- 73
- Issue
- 1
- Pages
- 20-30
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1981458531
- Cited by
- 266
- References
- 0
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. https://app.cochat.ai/papers/10.1067/mcp.2003.22
- The paper
- Csajka, C., Marzolini, C., Fattinger, K., Décosterd, L. A., Fellay, J., Telenti, A., Biollaz, J., & Buclin, T. (2003). Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clinical Pharmacology & Therapeutics. https://doi.org/10.1067/mcp.2003.22
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.